KMT2A and leukemia: SYC-522, a potent DOT1L inhibitor, was developed to inhibit the methylation at H3K79, decrease the expression of HOXA9 and MEISI and raise the sensitivity of MLL-rearranged leukemia cells presenting a potential means to treat MLL-rearranged leukemia [115].